

Asensus Surgical to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference

July 1, 2021

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Jul. 1, 2021-- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided SurgeryTM, announced today that Anthony Fernando, President and Chief Executive Officer, and Shameze Rampertab, Executive Vice President and Chief Financial Officer, will present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference. The virtual presentation is scheduled to take place at 8:30 am Eastern Time, Wednesday, July 14, 2021.

A live audio webcast of the conference presentation will be available online on the investor relations page of the Company's website at https://ir.asensus.com/events-and-presentations. Replays of the webcasts will be archived on the website for approximately 90 days.

About Asensus Surgical, Inc.

Asensus Surgical, Inc. is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery by unlocking the clinical intelligence to enable consistently superior outcomes and a new standard of surgery. This builds upon the foundation of Digital Laparoscopy with the Senhance[®] Surgical System powered by the Intelligent Surgical UnitTM (ISUTM) to increase surgeon control and reduce surgical variability. With the addition of machine vision, augmented intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. Learn more about Performance-Guided Surgery and Digital Laparoscopy with the Senhance Surgical System here: www.senhance.com. Now available for sale in the US, EU, Japan, Russia, and select other countries. For a complete list of indications for use, visit: www.senhance.com/indications. For more information, visit www.senhance.com/indications. For more

View source version on <u>businesswire.com</u>: https://www.businesswire.com/news/home/20210701005183/en/

INVESTOR CONTACT:

Mark Klausner or Mike Vallie, 443-213-0499 invest@asensus.com or

MEDIA CONTACT:

Kristin Schaeffer CG Life kschaeffer@cglife.com

Source: Asensus Surgical, Inc.